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所处融资环境，提出 A 公司未来的融资方式应为 IPO。在着重分析 IPO 的五力模型、风

























Biopharmaceutical industry is one of the most potential industry in twenty-first century, 
some countries including China have regarded it as source of strong economic growth. As the 
R&D has three distinct characters: high investment, high risk and long cycle, 
biopharmaceutical companies have some difficulty to obtain funding from general channels. 
Financing difficulty has become a key factor affecting the development of biopharmaceutical 
companies, lack of funding has become a major bottleneck restricting the development of 
China's biopharmaceutical companies. Investigating the financing problems and strategy of 
biopharmaceutical companies will be a great help to resolve their financing problems and 
promote the innovation and development of China's pharmaceutical industry. 
Biopharmaceutical companies face different risks and have different enterprise value at 
different stage of enterprise life cycle, so biopharmaceutical companies should take different 
financing strategy at different stages of life cycle. This article aim to investigate appropriate 
financing strategy which biopharmaceutical companies should take at different stage of life 
cycle through the theory of enterprises’ lifecycle. Firstly, it propose the division of life cycle 
for biopharmaceutical enterprise. As drugs are special commodities, the R&D, manufacturing 
and supplying of drugs are supervised and approved by the drug administration. The approval 
of clinical or manufacturing means a sharp decline in the risk of R&D and a significant 
increase of biopharmaceutical companies’ value. Therefore, the life cycle biopharmaceutical 
companies divided into seed stage, start-up stage, development stage and maturity stage 
according to the risk and value of the enterprise which is closely combined by the approval of 
drugs by the drug administration. Then detailed analyze the financing channels at each stage, 
the advantages and disadvantages of different financing strategies at different stage of life 
cycle. 
A biopharmaceutical company in life cycle of development stage is taken as an example, 
Firstly introduce A company’s profile and financing channels which A company has taken at 
different stages of life cycle. Then the current status of A company is focused on. It  
introduce A company’s capital needs, financing gap, financing environment and try to solve 

















best choice for A company. Then analyze five forces model for IPO and the risk, financial 
situation and IPO board selection for A company is growth enterprise board. 
At last it comes to an conclusion that biopharmaceutical companies should take 
appropriate financing strategy at different stage of the lifecycle according to the study of 
enterprises’ lifecycle. And no matter the stage of life cycle an enterprise at, biopharmaceutical 
companies should standardize enterprise internal management and strengthen external 
communication for the preparation of financing, break through the bottleneck of financing, 
promote the sustainable development. This article aims to financing strategy, making 
enterprise life cycle as research point, not only intends to solve the problems that A 
biopharmaceutical company meets, but also to provide some practical help to other 
biopharmaceutical companies in China. 
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